• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Invivyd Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/20/25 4:16:59 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IVVD alert in real time by email
    8-K
    0001832038false00018320382025-05-202025-05-20

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 20, 2025

     

     

    Invivyd, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

     

     

    Delaware

    001-40703

    85-1403134

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

    1601 Trapelo Road, Suite 178

    Waltham, MA

    02451

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Registrant’s telephone number, including area code: (781) 819-0080

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common stock, par value $0.0001 per share

    IVVD

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

     

    On May 20, 2025, Invivyd, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting and the final voting results as certified by the Company’s independent inspector of election in connection with the Annual Meeting.

     

    Proposal 1: The stockholders of the Company elected Tamsin Berry, Marc Elia, Christine Lindenboom, Terrance McGuire, Kevin F. McLaughlin and Ajay Royan as directors for a one-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. The votes were cast as follows:

     

    Nominee

     

    For

     

    Withheld

     

    Broker Non-Votes

    Tamsin Berry

     

    75,934,285

     

    164,643

     

    15,881,370

    Marc Elia

     

    72,814,843

     

    3,284,085

     

    15,881,370

    Christine Lindenboom

     

    73,721,796

     

    2,377,132

     

    15,881,370

    Terrance McGuire

     

    75,863,179

     

    235,749

     

    15,881,370

    Kevin F. McLaughlin

     

    73,789,790

     

    2,309,138

     

    15,881,370

    Ajay Royan

     

    75,950,649

     

    148,279

     

    15,881,370

     

    Proposal 2: The stockholders of the Company ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with votes cast as follows:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    91,799,959

     

    97,661

     

    82,678

     

    —

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    INVIVYD, INC.

    Date: May 20, 2025

    By:

    /s/ Jill Andersen

    Jill Andersen

    Chief Legal Officer and Corporate Secretary

     

     

     


    Get the next $IVVD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVVD

    DatePrice TargetRatingAnalyst
    4/5/2024$9.00Neutral → Buy
    Guggenheim
    3/26/2024$4.00 → $10.00Equal-Weight → Overweight
    Morgan Stanley
    12/19/2023$1.00 → $4.00Underweight → Equal-Weight
    Morgan Stanley
    5/1/2023$5.00Buy
    H.C. Wainwright
    More analyst ratings

    $IVVD
    Financials

    Live finance-specific insights

    See more
    • Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

      PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization dosesVYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025 WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIR

      5/15/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

      WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company's investor relations website approximately two

      5/8/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvementsPEMGARDA Fact Sheet updated to properly reflect neutralization activity of PEMGARDA against current circulating variants tested; on track for continued growth now reflective of ongoing commercial optimizationNext generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024Management to host conference call t

      11/14/24 7:05:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    SEC Filings

    See more
    • Invivyd Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Invivyd, Inc. (0001832038) (Filer)

      5/20/25 4:16:59 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Invivyd Inc.

      10-Q - Invivyd, Inc. (0001832038) (Filer)

      5/15/25 7:16:36 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Invivyd, Inc. (0001832038) (Filer)

      5/15/25 7:06:38 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mcguire Terrance

      4 - Invivyd, Inc. (0001832038) (Issuer)

      5/22/25 4:16:08 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Berry Tamsin

      4 - Invivyd, Inc. (0001832038) (Issuer)

      5/22/25 4:15:03 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mclaughlin Kevin F

      4 - Invivyd, Inc. (0001832038) (Issuer)

      5/22/25 4:14:02 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IVVD
    Leadership Updates

    Live Leadership Updates

    See more

    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

      WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in moderately to severely immunocompromised adults and adolescents (aged 12 or older) at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart. This inclu

      5/23/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

      FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requestsIn contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled trials to evaluate safety, immunogenicity, and exploratory efficacy in relevant, modern Americans, against relevant, modern immune-evasive SARS-CoV-2 viruses, and over the long-term Invivyd plans to advance next generation COVID-19 mAbs to improve product scalability and system-friendliness while preser

      5/21/25 9:30:23 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

      PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization dosesVYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025 WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIR

      5/15/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

      WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan's investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection from serious viral infectious diseases, starting with COVID-19. "We are delighted by Ajay's return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medica

      3/26/25 4:15:46 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

      Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and AmylyxAppointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to the ongoing PEMGARDA™ commercial launchWilliam Duke, Jr., Chief Financial Officer, appointed as Principal Executive Officer WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) --  Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Timothy Lee will be appointed Invivyd's Chief Commercial Officer and will join the company's executive leadership team. Mr. Lee's appointment follows th

      5/31/24 7:00:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Elects Two New Independent Members to its Board of Directors

      WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at the annual meeting of stockholders on May 21, 2024. Dr. Gupta will serve as the Chairperson of the Compensation Committee and Mr. McLaughlin will serve as the Chairperson of the Audit Committee. "We are delighted to welcome Dr. Gupta and Mr. McLaughlin to our Board during a transformational period of growth for the company," said Marc Elia, Chairman of the Invivyd Board of Direc

      5/22/24 7:00:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd upgraded by Guggenheim with a new price target

      Guggenheim upgraded Invivyd from Neutral to Buy and set a new price target of $9.00

      4/5/24 7:50:41 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Invivyd from Equal-Weight to Overweight and set a new price target of $10.00 from $4.00 previously

      3/26/24 8:01:17 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Invivyd from Underweight to Equal-Weight and set a new price target of $4.00 from $1.00 previously

      12/19/23 7:28:14 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

      SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

      12/12/24 4:39:09 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

      SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

      11/14/24 4:30:58 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

      SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

      11/14/24 9:16:35 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care